Regeneron Pharmaceuticals Inc. filings document the regulatory disclosures of a biotechnology operating company with marketed medicines, clinical programs and collaboration-driven research activity. Recent Form 8-K reports furnish quarterly and annual financial and operating results, including GAAP and non-GAAP measures, product sales commentary, regulatory and pipeline updates, and acquired in-process research and development charges tied to collaboration, licensing and asset-acquisition activity.
The company's proxy materials cover governance and executive compensation matters, including pay-versus-performance data and equity award disclosures. Regeneron's SEC record also includes exhibit filings and Inline XBRL cover-page data associated with material-event reports, providing formal documentation of financial reporting, corporate governance and capital-allocation disclosures such as share repurchase authorization.
Regeneron Pharmaceuticals reports full-year 2025 revenue of $14,342.9M, up slightly from 2024, and net income of $4,504.9M, with diluted EPS of $41.48. Growth is driven by key biologics and extensive collaborations.
Flagship eye drugs EYLEA HD and EYLEA together generated $7,891.0M in 2025 net product sales, while Dupixent global net product sales reached $17,806.7M. Libtayo, Praluent, Kevzara and other products added diversified revenue across immunology, oncology and cardiovascular disease.
The company highlights a broad late-stage pipeline in ophthalmology, immunology, oncology, hematology, neurology and rare diseases, with multiple Phase 3 programs and upcoming regulatory decisions through 2026–2027. Regeneron also underscores its VelociSuite antibody platforms and Regeneron Genetics Center as core innovation engines, supported by major partnerships with Sanofi, Bayer, Alnylam, Intellia and others.
Regeneron Pharmaceuticals, Inc. filed a current report to furnish a press release announcing its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1 to the report.
The company states that the information provided under the results section, including Exhibit 99.1, is being furnished rather than filed under securities laws, which affects how it is treated for certain legal liabilities and incorporation by reference into other registration statements.
Regeneron Pharmaceuticals, Inc. used its appearance at the 44th Annual J.P. Morgan Healthcare Conference to share a corporate update that includes preliminary, unaudited financial information for the fourth quarter and full year 2025, furnished via an accompanying presentation.
For the fourth quarter 2025, Regeneron currently expects to record an acquired in-process research and development charge of approximately $19 million on a pre-tax basis, which is expected to reduce both GAAP and non-GAAP net income per diluted share by about $0.14. In addition, under its previously disclosed matching program supporting Good Days’ Retinal Vascular and Neovascular Disease Fund, Regeneron was notified of about $60 million in donations to the fund in the quarter, leading to a corresponding matching charge recorded in selling, general, and administrative expenses. All results remain preliminary and subject to completion of financial closing procedures.
Regeneron Pharmaceuticals director Bonnie L. Bassler reported an option exercise and share sale. On January 7, 2026, she exercised 1,500 Non-Qualified Stock Options with an exercise price of $374.12 per share, receiving 1,500 shares of common stock. That same day, she sold 1,500 common shares at a volume-weighted average price of $800.00 per share under a Rule 10b5-1(c) trading plan adopted on May 2, 2025. After these transactions, she directly held 1,703 shares of common stock and 2,861 stock options.
Regeneron Pharmaceuticals insider Bonnie Bassler has filed a Form 144 notice to sell common stock. The filing covers a proposed sale of 1500 common shares through broker RBC Capital Markets LLC, with an aggregate market value of 1200000.00 and 103282318 shares outstanding, to be sold on or about 01/07/2026 on NASDAQ.
The shares to be sold were acquired from the issuer on 01/07/2026 via an option exercise for 1500 shares, paid by check on the same date. The filing also notes that during the past three months, Bonnie Bassler sold 760 Regeneron Pharmaceuticals Inc securities on 11/20/2025 for gross proceeds of 570000.00.
Regeneron Pharmaceuticals director Craig B. Thompson reported new equity awards. On January 2, 2026, he acquired 155 time-based restricted stock units, each representing one share of Regeneron common stock, and 1,962 non-qualified stock options with a conversion (exercise) price of $772.76 per share.
After these grants, Thompson directly beneficially owned 775 shares of common stock and 1,962 stock options. A portion of the options will become exercisable on the date of Regeneron’s first annual shareholder meeting following the grant, in proportion to the part of a year that has elapsed since grant, with the remaining options becoming exercisable on the first anniversary of the grant date.
Regeneron Pharmaceuticals director George L. Sing reported new equity awards in company stock. On January 2, 2026, he acquired 155 shares of common stock at a price of $0.0 per share, described as time-based vesting restricted stock units that each represent a right to receive one share of common stock. On the same date, he received a non-qualified stock option to buy 1,962 shares of common stock at an exercise price of $772.76 per share, expiring on January 2, 2036.
Following these awards, Sing directly beneficially owns 31,007 shares of Regeneron common stock. Additional indirect holdings reported include 750 shares by his spouse, 400 shares by his spouse as custodian for their son, and 1,000 shares held in a trust for their son. A portion of the stock options becomes exercisable on the date of the first annual shareholder meeting following the grant, with the remainder exercisable on the first anniversary of the grant date.
Regeneron Pharmaceuticals director David P. Schenkein reported new equity awards. On 01/02/2026, he acquired 1,962 non-qualified stock options with an exercise price of $772.76 per share, each option linked to Regeneron common stock. A portion of these options becomes exercisable on the date of the company’s first annual shareholder meeting following the grant, with the remainder vesting on the first anniversary of the grant date.
He also acquired 155 time-based restricted stock units, each representing a contingent right to receive one share of Regeneron common stock. Following this grant, he beneficially owned 603 shares of common stock directly.
Regeneron Pharmaceuticals director Joseph L. Goldstein reported new equity awards. On 01/02/2026, he was granted 1,962 non-qualified stock options with an exercise price of $772.76 per share, each option linked to one share of common stock. A footnote explains that part of these options becomes exercisable on the date of the company’s first annual shareholder meeting following the grant, with the remainder vesting on the first anniversary of the grant date. He also acquired 155 time-based vesting restricted stock units, each representing a contingent right to receive one share of common stock at no purchase price. Following these transactions, he directly beneficially owned 1,962 stock options and 6,703 shares of common stock.
Regeneron Pharmaceuticals director Michael S. Brown reported new equity awards. On January 2, 2026, he received 155 time-based restricted stock units, each representing one share of Regeneron common stock, bringing his directly held common stock to 1,703 shares. He was also granted a non-qualified stock option for 1,962 shares with an exercise price of $772.76 per share, expiring on January 2, 2036; a portion becomes exercisable on the date of the first annual shareholder meeting after the grant, with the remainder on the first anniversary of the grant date.
In addition, the filing lists 5,000 shares held indirectly by a SLAT and 6,162 shares held indirectly by a trust. The trust is for the benefit of Brown’s immediate family, his spouse is trustee, and he disclaims beneficial ownership of those trust-held securities.